Report error Found 445 Enz. Inhib. hit(s) with all data for entry = 12869
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetRAF Proto-oncogen Serine/Threonine-Protein Kinase/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50S for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair































